| Market Cap | 15.50M | P/E | - | EPS this Y | 74.20% | Ern Qtrly Grth | - |
| Income | -20.13M | Forward P/E | -1.51 | EPS next Y | 83.30% | 50D Avg Chg | 15.00% |
| Sales | 34.07M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -21.00% |
| Dividend | N/A | Price/Book | 0.93 | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | 2.00 | Quick Ratio | 0.36 | Shares Outstanding | 5.09M | 52W Low Chg | 57.00% |
| Insider Own | 28.19% | ROA | -33.86% | Shares Float | 2.63M | Beta | 0.66 |
| Inst Own | 40.60% | ROE | -140.43% | Shares Shorted/Prior | 23.81K/34.77K | Price | 11.61 |
| Gross Margin | 48.80% | Profit Margin | -59.09% | Avg. Volume | 24,828 | Target Price | 16.00 |
| Oper. Margin | -36.48% | Earnings Date | Aug 11 | Volume | 2,832 | Change | -2.11% |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Benchmark | Buy | Aug 31, 23 |